瑞格列奈治疗初发2型糖尿病200例疗效观察  

Repaglinide for treatment of newly diagnosed type 2 diabetes mellifus

作　　者：杨架林[1] 沈春芳[1] 孙珏 李雪松[1] 张钰[1] 张宁[1] 范晓方[1] 任风东[1] 任国光[1] 

机构地区：[1]上海瑞金医院集团闵行区中心医院内分泌科,201199

出　　处：《蚌埠医学院学报》2011年第10期1090-1091,共2页Journal of Bengbu Medical College

摘　　要：目的:观察瑞格列奈治疗初发2型糖尿病的疗效。方法:对200例初发2型糖尿病患者在饮食控制及运动治疗基础上,给予瑞格列奈1 mg,每天3次,饭前服用,观察16周。分别于治疗8周及16周后测量体重指数、血脂、空腹血糖、餐后血糖、糖基化血红蛋白、空腹胰岛素水平。结果:治疗16周后患者的空腹血糖、餐后2 h血糖、糖基化血红蛋白水平均明显下降(P<0.01)。结论:瑞格列奈能有效控制2型糖尿病患者的血糖,不良反应少,且低血糖发生率低。Objective：To observe the efficacy of repaglinide in treatment of newly diagnosed type 2 diabetes mellitus.Methods：Two hundred patients who were newly diagnosed to have type 2 diabetes mellifus were administered repaglinide 1.0 mg 3 times a day before meals in addition to the therapy of diet-control and adequate exercise.And the effect was observed in the following 16 weeks.The BMI,blood fat,fasting blood glucose,blood glucose 2 hours after meals,HbA1C and fasting insulin at 8 weeks and 16 weeks after the therapy were detected.Results：After 16 weeks of treatment,the fasting blood glucose,blood glucose 2 hours after meals and HbA1C were significantly decreased（P0.01）.Conclusions：Repaglinide may effectively control the blood glucose of patients with type 2 diabetes with few adverse reactions and a low incidence of hypoglycemia.

关 键 词：糖尿病 2型 瑞格列奈 疗效 

分 类 号：R587.1[医药卫生—内分泌]